Postpartum Depression and Psychosis

Hormonal Fluctuations and Neuroendocrine Changes

• The dramatic withdrawal of estrogen and progesterone following placental delivery is the precipitating hormonal event. Throughout pregnancy, placental steroid production maintains high circulating levels; after delivery, these hormones decline >95% within 48-72 hours. This rapid fluctuation alters multiple neurotransmitter systems and HPA (hypothalamic-pituitary-adrenal) axis function.
• Serotonergic dysfunction is central to PPD pathogenesis. Estrogen enhances serotonergic neurotransmission by increasing tryptophan hydroxylase expression, monoamine oxidase B inhibition, and serotonin transporter (5-HTT) expression. The postpartum estrogen withdrawal leads to reduced serotonin synthesis and increased degradation, resulting in functional serotonergic deficiency. This mechanism explains why SSRIs are effective and why women with previous SSRi responsiveness may relapse postpartum.
• GABAergic system dysregulation occurs through altered allopregnanolone, a potent allosteric GABA-A receptor modulator produced from progesterone. Allopregnanolone levels rise during pregnancy and sharply decline postpartum, removing this neurosteroid's anxiolytic and mood-stabilizing effects. Women with PPD may have enhanced sensitivity to allopregnanolone fluctuations or impaired adaptation to its withdrawal. This mechanism is distinct from major depression and explains potential efficacy of brexanolone (allopregnanolone replacement) in PPD.

Inflammatory and Immunological Mechanisms

• Inflammatory cytokine elevation (TNF-α, IL-6, IL-1β, CRP) has been documented in women with PPD, particularly in those with elevated inflammatory markers during pregnancy. The normal postpartum switch from Th2 (anti-inflammatory) to Th1 (pro-inflammatory) immunity may be exaggerated in vulnerable women. This inflammatory milieu influences monoamine metabolism through IDO (indoleamine 2,3-dioxygenase) activation, shunting tryptophan toward the kynurenine pathway away from serotonin synthesis, and directly activates microglia producing neurotoxic mediators.
• Oxytocin dysregulation is implicated particularly in postpartum psychosis. Oxytocin, released during delivery and lactation, modulates dopamine and serotonin systems. Aberrant oxytocin signaling may contribute to both mood symptoms and psychotic features through dopaminergic dysfunction.

Genetic and Neurobiological Vulnerability

• Genetic predisposition is substantial: women with a family history of bipolar disorder have a 40-50% risk of postpartum psychosis following delivery, compared to 1-2 per 1,000 in the general population. Candidate genes include those affecting serotonin transporter (5-HTTLPR polymorphisms), BDNF (brain-derived neurotrophic factor), and estrogen receptor variants, though no single genetic marker is definitive.
• Neuroplasticity alterations: Pregnancy induces significant gray matter changes, particularly in regions mediating emotion processing (amygdala, prefrontal cortex, insula). Postpartum reorganization of these networks, combined with hormonal withdrawal, may unmask latent psychiatric vulnerability. Functional neuroimaging in PPD shows reduced activity in regions supporting emotion regulation (ventromedial prefrontal cortex) and reward processing (ventral striatum).
• HPA axis dysregulation: The normal pregnancy-induced HPA axis hyperresponsiveness (elevated cortisol without psychosis symptoms) fails to normalize postpartum in women with PPD. Elevated postpartum cortisol, combined with altered CRH signaling, perpetuates mood disturbance. This differs from non-perinatal depression where HPA abnormalities are similar.

Dopaminergic Dysfunction in Postpartum Psychosis

• PPP involves dopamine system dysregulation distinct from PPD. The combination of estrogen withdrawal (which normally inhibits dopamine synthesis) and rapid oxytocin changes may acutely increase dopaminergic tone, particularly in mesolimbic pathways, producing psychotic symptoms. This is supported by antipsychotic responsiveness and higher rates of bipolar spectrum disorders in women with PPP.

Sleep Disruption as Amplifying Mechanism

• The marked sleep deprivation inherent to postpartum care is a potent trigger and perpetuating factor. Sleep loss exacerbates hormonal dysregulation, impairs prefrontal emotion regulation, increases inflammatory markers, and destabilizes circadian rhythmicity. In women with bipolar disorder, postpartum sleep loss is a recognized psychosis trigger.

Major Risk Factors for Postpartum Depression

• Prior major depressive disorder or postpartum depression confers ~50% recurrence risk postpartum. Previous depression during pregnancy is even more predictive. Women with untreated or undertreated depression entering pregnancy have markedly elevated risk. Those with depression responsive to SSRIs should ideally remain on therapy throughout pregnancy and postpartum, as discontinuation dramatically increases relapse risk.
• Bipolar spectrum disorder carries significant PPD risk but more importantly, 40-50% risk of postpartum psychosis. Even women with remotely diagnosed bipolar disorder or family history of bipolar illness should be counseled about this risk. Mood stabilizers should generally be continued peripartum and intensified postpartum.

Obstetric/Medical Complications

• Perinatal mood-triggering events: Complicated deliveries, emergency cesarean, neonatal complications, or maternal medical complications trigger or exacerbate postpartum mood disorders by combining physiological stress with psychological trauma. Preeclampsia, postpartum hemorrhage requiring transfusion, or neonatal ICU admission substantially increase risk.
• Thyroid dysfunction: Postpartum thyroiditis, affecting 5-10% of women, can present as or exacerbate depression or psychosis. Hypothyroidism causes or mimics depression; hyperthyroidism can trigger psychotic features or manic symptoms. Screening TSH is warranted in all postpartum women with mood changes.

Psychosocial Risk Factors

• Marital discord, lack of social support, recent life stressors, and relationship difficulties with partner are among the strongest modifiable psychosocial predictors. These factors likely interact with biological vulnerability; their presence in biologically predisposed women substantially increases risk of severe depression or psychosis.
• Stress-related factors: Unplanned pregnancy, ambivalence about motherhood, or high life stress during pregnancy predict higher risk.

Socioeconomic and Demographic Factors

• Lower socioeconomic status, younger maternal age, and social isolation increase risk through multiple mechanisms (increased stress, reduced healthcare access, limited support). These are important for targeted screening and intervention in high-risk populations.

Protective and Amplifying Factors

• Breastfeeding initiation and continuation has been associated with reduced PPD risk in some studies, possibly through oxytocin effects and increased mother-infant bonding, though causality remains unclear.
• Multiparity: Some evidence suggests first-time mothers have slightly elevated risk compared to multiparous women, though psychiatric history is more predictive than parity.

Specific Risk for Postpartum Psychosis

• Family history of bipolar disorder or psychotic disorder is the most robust predictor; relatives of women with PPP have elevated bipolar spectrum disorder risk themselves.
• Bipolar I or II disorder history: 40-50% of women with bipolar disorder experience postpartum psychosis, often within days of delivery.
• Sleep deprivation triggers: Even in non-bipolar women, extreme sleep loss peripartum (e.g., from obstetric complications or overstimulation) can precipitate psychotic symptoms.

Postpartum Depression: Classic Presentation

Mood and Affective Symptoms

• Depressed mood: Persistent sadness, hopelessness, or emotional numbness lasting most of the day nearly every day. Women often describe feeling "flat," unable to enjoy infant or previously pleasurable activities. The depression may emerge gradually over 2-8 weeks postpartum or, in some cases, have onset during pregnancy.
• Anhedonia and loss of interest in infant: Inability to find joy in the newborn or feel maternal bonding is a hallmark feature distinguishing PPD from baby blues. Women report guilt about not feeling attached, fear they are "bad mothers," or worry they will harm the infant despite lacking intent to do so. This anhedonia extends to other activities and relationships.
• Anxiety symptoms: Postpartum anxiety is highly prevalent, with many women meeting criteria for generalized anxiety disorder, panic disorder, or obsessive-compulsive disorder in the postpartum period. Excessive worry about infant health, intrusive thoughts about harm coming to the infant (without desire to harm), and panic attacks occur frequently.

Cognitive Symptoms

• Impaired concentration and decision-making: Difficulty focusing, making decisions about infant care, or managing household tasks. Women describe "brain fog" and difficulty reading or processing information.
• Rumination and guilt: Excessive self-blame, guilt about not being a "good enough mother," feelings of worthlessness, and rumination about errors or perceived failures.

Somatic and Neurovegetative Symptoms

• Sleep disturbance beyond that expected postpartum: Insomnia despite infant napping (in contrast to baby blues sleep loss driven solely by infant demands) or hypersomnia/difficulty waking.
• Appetite changes: Decreased appetite or, less commonly, increased appetite with weight loss or gain.
• Fatigue and decreased energy: Marked fatigue distinguishable from normal postpartum exhaustion, with lack of energy disproportionate to sleep disruption.
• Psychomotor changes: Agitation or retardation may be observable.

Behavioral and Relational Symptoms

• Social withdrawal: Isolation from friends, family, and partner; reduced initiation of social contact.
• Marital discord and sexual dysfunction: Decreased libido, sexual aversion, and relationship strain are common, compounding isolation.

Physical Exam Findings in PPD

• Appearance: Neglected grooming, poor hygiene, or flattened affect may be observed.
• Psychomotor findings: Retardation (slowed movement and speech) or agitation (fidgeting, pacing).
• Lack of engagement with infant: Mother may hold infant in perfunctory manner without eye contact, vocalization, or engagement (though this requires interpretation within cultural context).

Postpartum Psychosis: Clinical Presentation

Acute Onset and Temporal Profile

• Onset within 2-14 days postpartum (earlier than PPD), with presentation often described as abrupt change in mental status by family members. The rapid deterioration distinguishes PPP from insidious PPD onset.

Psychotic Features

• Delusions: Often mood-congruent but may be bizarre. Common themes include:
• Delusions of reference (believing staff is watching or plotting against her)
• Persecutory delusions (belief that infant will be harmed or taken away)
• Command hallucinations (voices instructing harm to self or infant) - present in ~20% of cases
• Delusions about the infant (false belief that infant is possessed, evil, or not her own)
• Grandiose delusions (feeling specially chosen or able to prevent disaster)

• Hallucinations: Auditory hallucinations are most common (voices, often multiple, with command content), followed by visual hallucinations. Tactile or somatic hallucinations occur less frequently.

Mood Disturbance

• Rapidly alternating mood states: Women may swing from depressed to euphoric to dysphoric within hours.
• Severe anxiety and agitation: Often exceeds that seen in PPD alone.
• Emotional lability: Rapid, unprovoked changes in affect.

Behavioral Changes

• Bizarre or inappropriate behavior: Disorganized behavior, bizarre dress or hygiene, sexual disinhibition, or inappropriate affect.
• Infant-related safety concerns: Neglect of infant care, inappropriate interactions (e.g., excessive stimulation or rough handling based on delusional content), or expressions of inability to care for infant safely due to psychotic content. Infanticide risk is significantly elevated but remains statistically rare (infanticide occurs in <1% of women with PPP).

Sleep Disturbance

• Marked insomnia without fatigue: Absence of sleepiness despite days without sleep (distinct from depression-related insomnia). This is sometimes called "sleep without sleepiness."

Physical Exam and Observable Features

• Thought disorganization: Speech may be incoherent, tangential, or show loose associations.
• Severe psychomotor agitation or catatonia: May require emergency psychiatric intervention.

Important Clinical Variants

• Overlap syndrome: Many women present with mixed features of depression, anxiety, and psychotic symptoms rather than "pure" postpartum psychosis. Psychotic features may emerge during severe depression.
• Atypical presentations: Some women with postpartum psychosis present primarily with severe anxiety and agitation before frank psychotic symptoms become apparent, leading to initial misdiagnosis as anxiety disorder.

"Baby Blues" (Postpartum Blues) - Differential Consideration

• Onset: Peak 3-5 days postpartum; resolves by day 14
• Mood lability: Rapid mood swings between euthymia and mild dysphoria
• Crying episodes: Episodic, brief crying often without clear trigger
• No anhedonia regarding infant: Mother is engaged with infant despite lability
• No psychosis or suicidality
• No impaired functioning: Mother manages basic self-care and infant care
• The key distinguishing feature: Baby blues spares the mother-infant relationship and does not impair care

Clinical Assessment

History and Risk Stratification

• Obtain detailed psychiatric history including previous depressive episodes, bipolar disorder, psychosis, or psychiatric hospitalizations. Specifically ask about response to psychotropic medications (SSRIs, mood stabilizers) and any postpartum psychiatric episodes.
• Clarify symptom onset timing: Baby blues (≤2 weeks, peaks days 3-5) versus PPD (2-8 weeks postpartum onset, may extend into months) versus PPP (days 2-14).
• Document pregnancy and delivery complications: Preeclampsia, hemorrhage, neonatal complications, or unexpected complications that may contribute psychologically.
• Assess psychosocial stressors: Relationship quality, presence of partner support, recent losses, financial stress, and social isolation. Explore for domestic violence (postpartum period is high-risk).
• Screen for previous perinatal psychiatric episodes: Prior PPD, pregnancy depression, or prior postpartum psychosis dramatically increase recurrence risk.

Mental Status Examination

• Appearance and behavior: Note grooming, hygiene, eye contact, psychomotor activity (retardation vs agitation), and appropriateness.
• Speech: Assess for rate, rhythm, pressured speech, or poverty of speech.
• Mood and affect: Ask "How is your mood?" Distinguish stated mood from displayed affect. Note affect appropriateness, range, and lability.
• Thought process: Assess organization (logical vs tangential vs incoherent). Listen for racing thoughts or flight of ideas.
• Thought content: Specifically ask about:
• Depressive content: Guilt, worthlessness, hopelessness
• Suicidal ideation: "Have you thought about harming yourself?" "Do you have a plan?" Screen for intent and leth

Immediate stabilisation (postpartum psychosis)

• Psychiatric emergency: ACOG treats PPP as an emergency requiring same-day psychiatric evaluation and, in most cases, inpatient admission. The mother should never be left alone with the infant until risk is formally assessed; ask directly about command hallucinations and delusions involving the baby.
• Antipsychotic plus mood stabiliser: a second-generation antipsychotic (e.g., risperidone, olanzapine) for acute psychosis and agitation, with lithium for the underlying bipolar diathesis that underlies most PPP. Short-term benzodiazepines restore sleep, itself a destabilising trigger.
• Electroconvulsive therapy: rapid, highly effective, and favoured for psychotic depression, catatonia, refusal of food/fluids, or imminent suicide/infanticide risk.

First-line therapy for postpartum depression

• SSRIs: sertraline is the usual first choice because of low transfer into breast milk; ACOG endorses SSRIs as first-line pharmacotherapy for moderate–severe PPD. Mechanism: restores serotonergic tone lost with estrogen withdrawal. Start low, titrate to a full antidepressant dose, and continue at least 6–12 months after remission.
• Psychotherapy: cognitive-behavioural therapy or interpersonal therapy is first-line for mild–moderate disease and is recommended by USPSTF as preventive counselling for at-risk pregnant/postpartum women.

Escalation

• Neuroactive steroid GABA-A modulators: these replace the allopregnanolone withdrawn after delivery and act within days rather than weeks — reserved for moderate–severe PPD.
• Brexanolone: 60-hour continuous IV infusion, REMS-restricted with continuous pulse oximetry and a monitored inpatient/certified setting. High-yield for exams, but its commercial availability in the US has been withdrawn/curtailed by the manufacturer and the logistics of a multi-day monitored infusion made it uncommon even before that — it is now rarely used in practice.
• Zuranolone: oral, 14-day course, and has largely supplanted brexanolone as the practical neurosteroid option for PPD.
• Switch SSRI, add SNRI or bupropion, or augment; consider ECT for treatment-resistant or severely suicidal patients.

Contraindicated / cautions

• Antidepressant monotherapy in suspected bipolar disorder or PPP risks a manic or psychotic switch — stabilise the mood first.
• Valproate should be avoided in reproductive-age women given teratogenicity if another pregnancy occurs.
• Lithium is not absolutely incompatible with breastfeeding but demands maternal and infant level, renal, and thyroid monitoring.

Maternal emergencies

• Suicide: mental health conditions, including suicide and overdose, are among the leading causes of pregnancy-associated death in the year after delivery in US maternal mortality review data. Signalled by hopelessness, a stated plan, or an affirmative answer to the self-harm item of the Edinburgh Postnatal Depression Scale — this mandates immediate safety assessment, not a routine follow-up appointment.
• Infanticide / neonaticide: driven by delusional content (infant is "evil," "possessed," or must be "saved") or command hallucinations in postpartum psychosis. Statistically rare but the reason PPP is admitted rather than managed outpatient.
• Neglect and unintentional harm: disorganisation and catatonia impair feeding and supervision.

Non-emergent maternal and infant sequelae

• Impaired mother–infant bonding: reduced maternal responsiveness degrades attachment; downstream infant failure to thrive, insecure attachment, and later cognitive/behavioural delay.
• Chronic or recurrent illness: untreated PPD frequently becomes chronic depression; PPP carries high recurrence with subsequent deliveries and usually declares an underlying bipolar disorder.

Treatment-related complications

• SSRIs: manic or psychotic switch if bipolarity is unrecognised; hyponatremia (SIADH), GI upset, sexual dysfunction; serotonin syndrome (clonus, hyperthermia, agitation) with serotonergic combinations — an emergency.
• Brexanolone: excessive sedation and sudden loss of consciousness, the reason for its REMS with continuous pulse oximetry and a required attendant for infant care.
• Zuranolone: CNS depression and driving impairment; patients must not drive for a defined interval after each dose.
• Lithium: toxicity precipitated by postpartum dehydration or NSAIDs — coarse tremor, ataxia, confusion; also hypothyroidism and nephrogenic diabetes insipidus.
• Antipsychotics: extrapyramidal symptoms, metabolic syndrome, hyperprolactinemia; neuroleptic malignant syndrome (rigidity, hyperthermia, elevated CK) is an emergency.
• ECT: transient anterograde and retrograde amnesia (typically for the period around treatment) and post-ictal confusion.

• Timing is the discriminator: blues peak days 3–5 and resolve by 2 weeks; postpartum psychosis erupts abruptly within the first 2 weeks; PPD builds over weeks to months. A stem giving "day 4, tearful, caring well for the baby" wants reassurance and follow-up — not an SSRI.
• The single best next step in suspected postpartum psychosis is hospitalisation with supervision of the infant. Do not start an outpatient SSRI, and do not send her home with the baby.
• The association examiners test: postpartum psychosis is a bipolar spectrum illness. A family or personal history of bipolar disorder is the strongest predictor, and unopposed antidepressant therapy can precipitate mania.
• Edinburgh Postnatal Depression Scale is the validated screen and deliberately omits somatic items that overlap with normal puerperium. Item 10 screens self-harm — any positive response triggers immediate risk assessment. ACOG (2023) recommends screening for depression and anxiety at the initial prenatal visit, later in pregnancy, and at postpartum visits, with full diagnostic assessment and follow-up for positive screens; AAP supports screening mothers at well-child visits.
• Sertraline is the classic answer for a breastfeeding mother with PPD (low milk transfer). Breastfeeding is not a reason to withhold treatment.
• Neurosteroid therapy: brexanolone is IV allopregnanolone; zuranolone is an oral neuroactive steroid analogue — both are positive allosteric modulators of GABA-A that correct the postpartum neurosteroid crash. Brexanolone is a 60-hour IV infusion under REMS because of sudden loss of consciousness.
• Common distractor: intrusive ego-dystonic thoughts of harm that horrify the mother indicate postpartum depression/anxiety or OCD, not psychosis. Ego-syntonic, delusion-driven ideas about the infant indicate psychosis.
• Always check TSH — postpartum thyroiditis mimics both depression and agitated psychosis and is a cheap, testable confounder.
• ECT is the answer for the severely suicidal, catatonic, or refractory postpartum patient needing rapid response.